Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

Current Medical Science is a prominent academic journal dedicated to advancing knowledge in the fields of Medicine, Biochemistry, and Genetics. Published by SPRINGER with an ISSN of 2096-5230 and E-ISSN 2523-899X, this journal is based in China and serves as a vital resource for researchers, professionals, and students alike. With a focus on innovative research and emerging trends, Current Medical Science has established itself with an impactful presence, operating under Open Access guidelines to ensure wide dissemination of scientific findings. The journal's recognition is underscored by its impressive Scopus rankings, including a Q3 quartile placement in Biochemistry and Genetics as of 2023. It is noteworthy that the journal spans converged years from 2018 to 2024, providing a comprehensive platform for scholarly discussions and developments that drive the evolution of medical science. As it continues to publish influential research, Current Medical Science plays an essential role in bridging the gap between laboratory science and clinical application.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Biomedicines, published by MDPI, is a prestigious open-access journal dedicated to the rapidly evolving fields of biochemistry, genetics, and molecular biology, as well as broader aspects of medicine. Since its inception in 2013, Biomedicines has established itself as a leading platform for researchers, practitioners, and students to disseminate high-quality research and innovative findings, reflected in its impressive Q1 ranking in both the Biochemistry, Genetics and Molecular Biology and Medicine categories. With its commitment to accessibility and impactful scholarship, the journal has quickly garnered an international readership, positioning itself as a vital resource in advancing scientific knowledge and fostering collaboration in the biomedical community. Operating from its headquarters in Basel, Switzerland, Biomedicines continues to thrive with features such as rigorous peer review and a fast publication process, making it an essential journal for those looking to contribute to and stay updated in their respective fields.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Annals of Clinical and Analytical Medicine, published by BAYRAKOL MEDICAL PUBLISHER, is a premier open-access journal dedicated to advancing the field of clinical and analytical medicine. With the evolving landscape of healthcare, this journal serves as a crucial platform for the publication of high-quality research that encompasses a wide range of topics in medical science, offering insights into innovative clinical practices and analytical methodologies. The journal, identifiable by its E-ISSN 2667-663X, promotes the dissemination of knowledge by providing unrestricted access to its articles, thus ensuring that researchers, healthcare professionals, and students can stay abreast of the latest findings and developments. As it continues to gain recognition, Annals of Clinical and Analytical Medicine aims to foster an inclusive dialogue within the global medical community, encouraging collaboration and promoting high-impact research that addresses pressing healthcare challenges.